Team is using new approach that could be cheap and scalable and become the norm within five yearsProf Robin Shattock would have liked slightly longer to develop the revolutionary approach to vaccines that he is pretty sure will not only save lives in the Covid-19 pandemic but become the norm for vaccine development within five years.His team at Imperial College were working on Ebola and Lassa fever vaccines using new technology but had not got as far as human trials when a novel coronavirus started to kill thousands of people in Wuhan, China. Continue reading...
More like this (3)
Mixing and matching doses of different COVID-19 vaccines was an idea that scientists dismissed out of...Mixing and matching doses of different COVID-19 vaccines was an idea that scientists dismissed out of hand. Now they're taking it seriously.
Scientists, including Fauci, are facing off over whether to delay 2nd vaccine doses. Here's why the risk of more mutations from delaying shots may ultimately be worth it.
Summary List PlacementExperts are split on whether governments should delay the second doses of coronavirus vaccines...Summary List PlacementExperts are split on whether governments should delay the second doses of coronavirus vaccines to ensure more people get a first shot. Countries must decide what to do with their limited vaccine stock: Do they immunize more people with a first dose of a two-dose shot, which doesn't give them full protection against the coronavirus, or do they hold back doses so...
Phase 3 success rate of 95% for US firm’s treatment is promising for UK vaccine trialCoronavirus...Phase 3 success rate of 95% for US firm’s treatment is promising for UK vaccine trialCoronavirus – latest updatesSee all our coronavirus coverageHopes are rising for the Covid jab being developed by Oxford University, after Moderna became the second company to reveal impressive results from its vaccine trials.Interim results from phase 3 clinical trials of the Covid vaccine from US company Moderna has revealed...